Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix

References

• Alonzo DE, Zhang GG, Zhou D, et al. (2010). Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 27:608–18
   PubMed Web of Science ®Google Scholar
• Dai W, Guo Y, Zhang H, et al. (2015). Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. Int J Pharm 478:718–25
   PubMed Web of Science ®Google Scholar
• Gadaleta-Caldarola G, Infusino S, Divella R, et al. (2015). Sorafenib: 10 years after the first pivotal trial. Future Oncol 11:1863–80
   PubMed Web of Science ®Google Scholar
• Huang D, Zhang S, Zhong T, et al. (2016). Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy. Oncotarget 7:43616–28
   PubMed Web of Science ®Google Scholar
• Jia Z, Lin P, Xiang Y, et al. (2011). A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate. Eur J Pharm Biopharm 79:126–34
   PubMed Web of Science ®Google Scholar
• Liu C, Chen Z, Chen Y, et al. (2016). Improving oral bioavailability of sorafenib by optimizing the “spring” and “parachute” based on molecular interaction mechanisms. Mol Pharm 13:599–608
   PubMed Web of Science ®Google Scholar
• Mamaeva V, Sahlgren C, Lindén M. (2013). Mesoporous silica nanoparticles in medicine-recent advances. Adv Drug Deliv Rev 65:689–702
   PubMed Web of Science ®Google Scholar
• Minagawa K, Berber MR, Hafez IH, et al. (2012). Target delivery and controlled release of the chemopreventive drug sulindac by using an advanced layered double hydroxide nanomatrix formulation system. J Mater Sci Mater Med 23:973–81
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231–48
   PubMed Web of Science ®Google Scholar
• Raina SA, Alonzo DE, Zhang GG, et al. (2014). Impact of polymers on the crystallization and phase transition kinetics of amorphous nifedipine during dissolution in aqueous media. Mol Pharm 11:3565–76
   PubMed Web of Science ®Google Scholar
• Santos HA, Peltonen L, Limnell T, Hirvonen J. (2013). Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly water-soluble drugs. Curr Pharm Biotechnol 14:926–38
   PubMed Web of Science ®Google Scholar
• Shen SC, Ng WK, Chia LS, et al. (2013). Applications of mesoporous materials as excipients for innovative drug delivery and formulation. Curr Pharm Des 19:6270–89
   PubMed Web of Science ®Google Scholar
• Shi NQ, Yao J, Wang XL. (2014). Effect of polymers and media type on extending the dissolution of amorphous pioglitazone and inhibiting the recrystallization from a supersaturated state. Drug Dev Ind Pharm 40:1112–22
   PubMed Web of Science ®Google Scholar
• Singh A, Worku ZA, van den Mooter G. (2011). Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv 8:1361–78
   PubMed Web of Science ®Google Scholar
• Stuurman FE, Nuijen B, Beijnen JH, Schellens JH. (2013). Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet 52:399–414
   PubMed Web of Science ®Google Scholar
• Ukmar T, Maver U, Planinšek O, et al. (2011). Understanding controlled drug release from mesoporous silicates: theory and experiment. J Control Release 155:409
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar HJ. (2009). Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692–706
   PubMed Web of Science ®Google Scholar
• Vialpando M, Martens JA, van den Mooter G. (2011). Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs. Ther Deliv 2:1079–91
   PubMedGoogle Scholar
• Wang XQ, Fan JM, Liu YO, et al. (2011). Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm 419:339–46
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. (2015). Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine 11:313–27
   PubMed Web of Science ®Google Scholar
• Wani A, Muthuswamy E, Savithra GH, et al. (2012). Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone. Pharm Res 29:2407–18
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–44
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–109
   PubMed Web of Science ®Google Scholar
• Xu W, Riikonen J, Lehto VP. (2013). Mesoporous systems for poorly soluble drugs. Int J Pharm 453:181–97
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang H, Gao C, et al. (2013). Highly ordered mesoporous carbon nanomatrix as a new approach to improve the oral absorption of the water-insoluble drug, simvastatin. Eur J Pharm Sci 49:864–72
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang H, Li C, et al. (2014). A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib. Pharm Res 31:1059–70
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang H, Che E, et al. (2015). Development of novel mesoporous nanomatrix-supported lipid bilayers for oral sustained delivery of the water-insoluble drug, lovastatin. Colloids Surf B Biointerfaces 128:77–85
   PubMed Web of Science ®Google Scholar
• Zhang Z, Niu B, Chen J, et al. (2014). The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials 35:4565–72
   PubMed Web of Science ®Google Scholar